Workflow
康拓医疗(688314) - 2022 Q1 - 季度财报

Financial Performance - Revenue for Q1 2022 reached ¥53,501,448.21, an increase of 30.15% compared to the same period last year[5] - Net profit attributable to shareholders was ¥18,031,944.39, reflecting a growth of 29.25% year-over-year[5] - Net profit excluding non-recurring gains and losses increased by 63.68% to ¥17,721,527.77[5] - Basic earnings per share for the period was ¥0.31, a decrease of 3.13% compared to the previous year[6] - The company achieved a main business revenue of 53.50 million RMB, a year-on-year increase of 30.15%[15] - Operating profit for Q1 2022 was ¥21,243,683.61, up 31.5% from ¥16,128,936.29 in the same period last year[23] - Net profit for Q1 2022 was ¥17,578,386.38, representing a 28.5% increase compared to ¥13,735,757.86 in Q1 2021[24] Cash Flow - Net cash flow from operating activities was ¥15,656,175.96, up 113.71% year-over-year[5] - The increase in operating cash flow was attributed to higher sales revenue and stable cash outflows compared to the previous year[10] - Cash flow from operating activities increased to ¥15,656,175.96 in Q1 2022, compared to ¥7,325,746.34 in Q1 2021, marking a 114.8% rise[26] - The company reported a net cash increase of ¥183,439,754.46 at the end of Q1 2022, down from ¥71,642,038.21 at the end of Q1 2021[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥600,780,145.86, representing a 4.78% increase from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to 600.78 million RMB, compared to 573.38 million RMB at the end of 2021[20] - Total liabilities increased to 81.89 million RMB from 71.98 million RMB year-on-year[20] - The equity attributable to shareholders reached 521.27 million RMB, up from 503.32 million RMB at the end of 2021[20] Research and Development - R&D investment totaled ¥2,481,241.25, down 39.27% compared to the previous year[6] - R&D expenditure as a percentage of revenue was 4.64%, a decrease of 5.30 percentage points year-over-year[6] - Research and development expenses decreased to ¥2,481,241.25 in Q1 2022 from ¥4,085,590.97 in Q1 2021, a reduction of 39.3%[23] - The company’s research project "3D printed PEEK cranial system" received approval for special review, expediting its market entry[16] Revenue Breakdown - Revenue from PEEK material cranial repair fixation products was 31.47 million RMB, growing by 30.43% year-on-year[15] - Revenue from titanium material cranial repair fixation products was 15.90 million RMB, with an 8.73% year-on-year increase[15] - The PEEK material sternum fixation system generated revenue of 2.07 million RMB, a significant increase of 514.11% year-on-year[15] Other Financial Metrics - Total operating costs for Q1 2022 were ¥31,854,707.27, an increase of 18.2% from ¥26,951,005.33 in Q1 2021[23] - The company experienced a decrease in other comprehensive income, reporting a net loss of ¥86,782.24 in Q1 2022 compared to a gain of ¥449,491.56 in Q1 2021[24] - Cash flow from investing activities showed a net outflow of ¥170,936,303.22 in Q1 2022, worsening from a net outflow of ¥27,985,345.84 in Q1 2021[26] Market Activities - The company increased its market promotion efforts, contributing to the rise in revenue[9] - The company completed a 16.67% equity investment in BPA, facilitating the introduction of a wireless intracranial pressure monitor[16]